A new stem cell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.
The "DHT itch" is real and likely due to inflammation at the hair follicle, exacerbated by increased testosterone or androgens. Treatments mentioned include dutasteride, minoxidil, finasteride, and various topical solutions.
A 20-year-old male has been experiencing hair loss for three years due to a vitamin D deficiency and has seen no improvement after 3.5 months of taking supplements. Another person suggested that if the hair loss follows a pattern, it might be regular baldness rather than due to the deficiency.
A 40+ year old is regrowing their hairline using microneedling, minoxidil, tretinoin, low-level laser therapy, massages, and Nizoral, without using finasteride or dutasteride. They noted progress in hair growth below a birthmark, an area that hadn't seen growth since their teenage years.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.
A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.
A 27-year-old has seen hair regrowth over 5 months using 2ml of 5% minoxidil daily, 50mg of RU58841 daily, and occasional microneedling. Commenters think the results are good and ask about microneedling frequency, needle size, and if ketoconazole shampoo is used.
A 37-year-old man reports significant hair regrowth using a regimen of topical minoxidil, oral finasteride, derma rolling, and saw palmetto shampoo, but notices uneven progress between the sides of his head. He theorizes that sleeping on one side might affect hair growth, but others suggest it could be unrelated to sleeping habits.
The user experienced better hair thickening results with a combination pill of oral minoxidil (3mg) and finasteride (1mg) compared to previous treatments with topical minoxidil and finasteride alone. They reported no significant side effects and expressed regret for not starting this treatment earlier.
The user is experiencing hair regrowth after using spironolactone, minoxidil 5%, and various supplements. They plan to purchase men's minoxidil for cost efficiency and use Nizoral shampoo and an oil blend for hair care.
PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.
The user shared their bloodwork results showing DHT at 17 ng/dl and testosterone at 287 ng/dl, with a slight Vitamin D deficiency. They are seeking opinions on these levels and have an upcoming dermatologist appointment.
A young male in his twenties discusses hair loss, mentioning the use of Minoxidil, topical finasteride, and occasional derma rolling. He inquires about scalp inflammation, fibrosis, and the potential benefits of magnesium oil and scalp massages for improving blood flow and hair health.
Maintaining scalp hair and minimizing shedding, treatments used such as Procapil, supplements, topical caffeine, topical estrogen, and scalp massage; suggestions for anagen extenders or pharmaceuticals to help with a short anagen phase.
A user with high pre-finasteride estrogen levels is asking if they need to normalize their hormone levels before starting finasteride and whether they should postpone dermarolling until they begin finasteride. The user is 21.5 years old.
An 18-year-old is using topical minoxidil 5% and derma rolling weekly for hair regrowth after shaving their head, while also addressing vitamin D deficiency and thyroid imbalance. They are questioning if the changes observed are signs of regrowth.
Microneedling can promote hair growth, but there is uncertainty about the best practices, including needle length, device, and session frequency. Users discuss using needle lengths between 0.5mm and 1.5mm, with some experiencing pinpoint bleeding, and emphasize the need for more reliable resources and guidelines.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.
Two twins who used Minoxidil, finasteride and dermarollers to treat their androgenic alopecia over a 10 month time period. The user is providing details on the process they use for dermarolling.
Minoxidil can inhibit collagen production, potentially causing premature aging. The user is inquiring if Vitamin C serum or derma rolling can counteract this effect.
Scientists at UCLA have developed a promising treatment for male pattern baldness using a molecule called PP405, which can potentially stimulate dormant hair follicles. Initial trials showed significant results within a week, but larger clinical trials are needed to confirm its efficacy and safety.
Blocking DHT may slow down aging and improve skin, with users reporting positive effects from finasteride. Minoxidil and RU58841 are also mentioned as treatments.
User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.
Concerns about CosmeRNA safety mechanisms and potential side effects. Discussion includes comparisons to Fluridil and questions about nanoparticle specificity and siRNA stability.
The user visited a trichologist due to ineffective topical finasteride treatment for hair loss. The trichologist recommended a new regimen including a two-month course of locoidon (cortisone 0.1%), followed by a solution containing minoxidil, hydrocortisone butirrate, estrone, progesterone, tocopherol acetate, trichosol, and transcutol.
Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.
The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.